Newspaper Advertisement of the Financial Statements Quarter ended & Nine months ended 31st December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals has filed the newspaper publication of its unaudited financial results for the quarter and nine months ended December 31, 2025. On a standalone basis, Q3 FY26 revenue jumped to Rs. 16,092.33 lakhs from Rs. 10,269.67 lakhs in Q3 FY25, a year-on-year rise of about 57%. Net profit after tax nearly doubled to Rs. 1,047.81 lakhs from Rs. 533.26 lakhs. Basic EPS for the quarter rose to Rs. 19.53 from Rs. 11.29. For the nine-month period, standalone revenue grew to Rs. 42,606.97 lakhs (from Rs. 28,886.10 lakhs) and net profit after tax climbed to Rs. 2,697.62 lakhs (from Rs. 1,373.58 lakhs), with 9M basic EPS at Rs. 50.27 versus Rs. 29.09 last year. Consolidated figures closely mirror the standalone numbers, indicating limited contribution from subsidiaries.
Sharp year-on-year growth in both revenue (around 47-57%) and net profit (nearly doubled) signals strong operational momentum, which is likely to be viewed positively by shareholders. Investors should watch for the full results PDF on BSE for segment-level detail and margin commentary.